The authors would like to thank Kaitlyn T. Bifolck for her help with language editing and manuscript formatting.
Dr. Winer has disclosed that he serves on the advisory board for Tesaro, Inc.; Genentech, Inc.; Leap Therapeutics, Inc.; and Puma Biotechnology, Inc. The remaining authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
This study received funding from the Breast Oncology Center at Dana-Farber Cancer Institute and from Università degli Studi di Genova.
This study was partly presented as a poster presentation at the joint symposium of the Dana-Farber/Harvard Cancer Center Programs in Breast Cancer and Gynecologic Cancers; March 4, 2016; Boston, MA, and was selected for e-publication in the 2016 ASCO Annual Meeting; June 3–7, 2016; Chicago, Illinois.
WangYYinQYuQ. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments. Breast Cancer Res Treat2011;130:489–498.
EisenhauerEATherassePBogaertsJ. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer2009;45:228–247.
GradisharWJAndersonBOBalassanianR. Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw2016;14:324–354.
CardosoFSenkus-KonefkaEFallowfieldL. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol2010;21(Suppl 5):v15–19.
CardosoFCostaANortonL. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol2014;25:1871–1888.
Fact Sheet: Tumor Markers. National Cancer Institute Web site. Available at: https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-fact-sheet. Accessed February 10 2017.
HarrisLFritscheHMennelR. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol2007;25:5287–5312.
Van PoznakCSomerfieldMRBastRC. Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol2015;33:2695–2704.
SmerageJBBarlowWEHortobagyiGN. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol2014;32:3483–3489.
AccordinoMKWrightJDVasanS. Use and costs of disease monitoring in women with metastatic breast cancer. J Clin Oncol2016;34:2820–2826.
Department of Health and Human ServicesCenters for Medicare & Medicaid Services. Medicare Learning Network: Medicare Coverage of Imaging Services. Available at: https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/downloads/Radiology_FactSheet_ICN907164.pdf. Accessed February 27 2017.
CochetADygai-CochetIRiedingerJM. 18F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations. Eur J Nucl Med Mol Imaging2014;41:428–437.
SenFAkpinarATOgurU. The impact of PET/CT imaging performed in the early postoperative period on the management of breast cancer patients. Nucl Med Commun2013;34:571–576.
RieggerCHerrmannJNagarajahJ. Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients. Eur J Nucl Med Mol Imaging2012;39:852–863.
GroheuxDMorettiJLBailletG. Effect of (18)F-FDG PET/CT imaging in patients with clinical stage II and III breast cancer. Int J Radiat Oncol Biol Phys2008;71:695–704.
KoolenBBVrancken PeetersMJAukemaTS. 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques. Breast Cancer Res Treat2012;131:117–126.
Centers for Medicare & Medicaid Services. Addendum A and Addendum B Updates. Available at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Addendum-A-and-Addendum-B-Updates.html. Last updated: December102012. Accessed February 27 2017.
BrufskyAMMayerMRugoHS. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res2011;17:4834–4843.
LinNUVanderplasAHughesME. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer2012;118:5463–5472.
MillerKDWeathersTHaneyLG. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol2003;14:1072–1077.
Di GioiaDHeinemannVNagelD. Kinetics of CEA and CA15-3 correlate with treatment response in patients undergoing chemotherapy for metastatic breast cancer (MBC). Tumour Biol2011;32:777–785.
ParkerPAKudelkaABasen-EngquistK. The associations between knowledge, CA125 preoccupation, and distress in women with epithelial ovarian cancer. Gynecol Oncol2006;100:495–500.
Clinical Laboratory Fee Schedule. Centers for Medicare & Medicaid Services Web site. Available at: https://www.cms.gov/medicare/medicare-fee-for-service-payment/clinicallabfeesched/. Accessed February 10 2017.
American Society of Clinical Oncology. The state of cancer care in America, 2016: a report by the American Society of Clinical Oncology. J Oncol Pract2016;12:339–383.